From GlobeNewswire: 2025-05-12 16:35:00

ZyVersa Therapeutics, Inc. plans to start Phase 2a trials for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease by end of Q2-2025. Additionally, groundbreaking data shows Inflammasome ASC Inhibitor IC 100 can block microglial inflammasome activation, reducing neurotoxicity in Parkinson’s disease patients. The company raised $2.0 million in Q1-2025.

In their pipeline update, ZyVersa expects to treat the first patient with VAR 200 in a Phase 2a trial for diabetic kidney disease by June 2025. They plan to initiate a Phase 1 trial for IC 100 in overweight individuals at risk of cardiometabolic diseases in H1-2026. The company reported a net loss of approximately $2.3 million in Q1-2025.

ZyVersa Therapeutics aims to start Phase 2a trials for VAR 200 in patients with diabetic kidney disease and Phase 1 trials for IC 100 in overweight individuals at risk of cardiometabolic diseases. The company raised $2.0 million in Q1-2025 and reported a net loss of around $2.3 million for the period.



Read more at GlobeNewswire:: ZyVersa Therapeutics Reports First Quarter 2025 Financial